Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2014 (2014), Article ID 821969, 17 pages
http://dx.doi.org/10.1155/2014/821969
Review Article

Invasive Mold Infections in Solid Organ Transplant Recipients

1Université Paris Descartes, Sorbonne Paris Cité, Centre d’Infectiologie Necker Pasteur, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, 75015 Paris, France
2Institut Pasteur, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS URA3012, 75015 Paris, France

Received 4 August 2014; Accepted 3 November 2014; Published 23 November 2014

Academic Editor: Maurizio Sanguinetti

Copyright © 2014 Yoann Crabol and Olivier Lortholary. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. P. Kontoyiennis, K. A. Marr, B. J. Park et al., “Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the transplant-associated infection surveillance network (TRANSNET) database,” Clinical Infectious Diseases, vol. 50, no. 8, pp. 1091–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. G. Pappas, B. D. Alexander, D. R. Andes et al., “Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (Transnet),” Clinical Infectious Diseases, vol. 50, no. 8, pp. 1101–1111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Neofytos, J. A. Fishman, D. Horn et al., “Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients,” Transplant Infectious Disease, vol. 12, no. 3, pp. 220–229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Kauffman, A. G. Freifeld, D. R. Andes et al., “Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET),” Transplant Infectious Disease, vol. 16, no. 2, pp. 213–224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Bitar, D. Van Cauteren, F. Lanternier et al., “Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006,” Emerging Infectious Diseases, vol. 15, no. 9, pp. 1395–1401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Neofytos, S. Treadway, D. Ostrander et al., “Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience,” Transplant Infectious Disease, vol. 15, no. 3, pp. 233–242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. B. de Pauw, T. J. Walsh, J. P. Donnelly et al., “Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group,” Chinese Journal of Infection and Chemotherapy, vol. 46, no. 12, pp. 1813–1821, 2008. View at Google Scholar · View at Scopus
  8. J. S. Schieffelin, J. B. Garcia-Diaz, G. E. Loss et al., “Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment,” Transplant Infectious Disease, vol. 16, no. 2, pp. 270–278, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Imhof, S. A. Balajee, D. N. Fredricks, J. A. England, and K. A. Marr, “Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole,” Clinical Infectious Diseases, vol. 39, no. 5, pp. 743–746, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Auberger, C. Lass-Flörl, M. Aigner, J. Clausen, G. Gastl, and D. Nachbaur, “Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 9, Article ID dks189, pp. 2268–2273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Madureira, A. Bergeron, C. Lacroix et al., “Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin,” International Journal of Antimicrobial Agents, vol. 30, no. 6, pp. 551–554, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. W. J. Steinbach, D. K. Benjamin Jr., D. P. Kontoyiannis et al., “Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases,” Clinical Infectious Diseases, vol. 39, no. 2, pp. 192–198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Maschmeyer and T. F. Patterson, “Our 2014 approach to breakthrough invasive fungal infections,” Mycoses, vol. 57, no. 11, pp. 645–651, 2014. View at Publisher · View at Google Scholar
  14. W. J. Steinbach, K. A. Marr, E. J. Anaissie et al., “Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry,” Journal of Infection, vol. 65, no. 5, pp. 453–464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Lortholary, J.-P. Gangneux, K. Sitbon et al., “Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007),” Clinical Microbiology and Infection, vol. 17, no. 12, pp. 1882–1889, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Graf, S. M. Khani, E. Ott et al., “Five-years surveillance of invasive aspergillosis in a university hospital,” BMC Infectious Diseases, vol. 11, article 163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Morgan, K. A. Wannemuehler, K. A. Marr et al., “Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program,” Medical Mycology, vol. 43, supplement 1, pp. S49–S58, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Singh, R. K. Avery, P. Munoz et al., “Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients,” Clinical Infectious Diseases, vol. 36, pp. 46–52, 2003. View at Google Scholar
  19. J. Gavalda, O. Len, R. San Juan et al., “Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study,” Clinical Infectious Diseases, vol. 41, no. 1, pp. 52–59, 2005. View at Google Scholar
  20. P. Muñoz, I. Cerón, M. Valerio et al., “Invasive aspergillosis among heart transplant recipients: a 24-year perspective,” Journal of Heart and Lung Transplantation, vol. 33, no. 3, pp. 278–288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Lanternier, E. Dannaoui, G. Morizot et al., “A global analysis of mucormycosis in France: the RetroZygo study (2005–2007),” Clinical Infectious Diseases, vol. 54, no. 1, pp. S35–S43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. M. Roden, T. E. Zaoutis, W. L. Buchanan et al., “Epidemiology and outcome of zygomycosis: a review of 929 reported cases,” Clinical Infectious Diseases, vol. 41, pp. 634–653, 2005. View at Publisher · View at Google Scholar
  23. M. J. Rüping, W. J. Heinz, A. J. Kindo et al., “Forty-one recent cases of invasive zygomycosis from a global clinical registry,” The Journal of Antimicrobial Chemotherapy, vol. 65, no. 2, pp. 296–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Singh, J. M. Aguado, H. Bonatti et al., “Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome,” Journal of Infectious Diseases, vol. 200, no. 6, pp. 1002–1011, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. B. J. Park, P. G. Pappas, K. A. Wannemuehler et al., “Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006,” Emerging Infectious Diseases, vol. 17, no. 10, pp. 1855–1864, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Lanternier, H. Y. Sun, P. Ribaud, N. Singh, D. P. Kontoyiannis, and O. Lortholary, “Mucormycosis in organ and stem cell transplant recipients,” Clinical Infectious Diseases, vol. 54, no. 11, pp. 1629–1636, 2012. View at Publisher · View at Google Scholar
  27. H.-J. Tietz, D. Brehmer, W. Jänisch, and H. Martin, “Incidence of endomycoses in the autopsy material of the Berlin Charité Hospital,” Mycoses, vol. 41, supplement 2, pp. 81–85, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Chamilos, M. Luna, R. E. Lewis et al., “Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003),” Haematologica, vol. 91, no. 7, pp. 986–989, 2006. View at Google Scholar · View at Scopus
  29. B. Einollahi, M. Lessan-Pezeshki, V. Pourfarziani et al., “Invasive fungal infections following renal transplantation: a review of 2410 recipients,” Annals of Transplantation, vol. 13, no. 4, pp. 55–58, 2008. View at Google Scholar · View at Scopus
  30. A. Skiada, L. Pagano, A. Groll et al., “Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007,” Clinical Microbiology and Infection, vol. 17, no. 12, pp. 1859–1867, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Petrikkos, A. Skiada, O. Lortholary, E. Roilides, T. J. Walsh, and D. P. Kontoyiannis, “Epidemiology and clinical manifestations of mucormycosis,” Clinical Infectious Diseases, vol. 54, no. 1, pp. S23–S34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. J. L. Rodriguez-Tudela, J. Berenguer, J. Guarro et al., “Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases,” Medical Mycology, vol. 47, no. 4, pp. 359–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. O. Lortholary, G. Obenga, P. Biswas et al., “International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 10, pp. 4446–4450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. S. G. Revankar, D. A. Sutton, and M. G. Rinaldi, “rimary central nervous system phaeohyphomycosis: a review of 101 cases,” Clinical Infectious Diseases, vol. 38, no. 2, pp. 206–216, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Pagano, M. Akova, G. Dimopoulos, R. Herbrecht, L. Drgona, and N. Blijlevens, “Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 1, pp. i5–i14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Shoham, “Emerging fungal infections in solid organ transplant recipients,” Infectious Disease Clinics of North America, vol. 27, no. 2, pp. 305–316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Mak, B. Klinkenberg, K. Bartlett, and M. Fyfe, “Ecological niche modeling of Cryptococcus gattii in British Columbia, Canada,” Environmental Health Perspectives, vol. 118, no. 5, pp. 653–658, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Alberti, A. Bouakline, P. Ribaud et al., “Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients,” Journal of Hospital Infection, vol. 48, no. 3, pp. 198–206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. M.-P. Brenier-Pinchart, B. Lebeau, J.-L. Borel et al., “Community-acquired invasive aspergillosis and outdoor filamentous fungal spore load: a relationship?” Clinical Microbiology and Infection, vol. 17, no. 9, pp. 1387–1390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Chamilos, E. M. Marom, R. E. Lewis, M. S. Lionakis, and D. P. Kontoyiannis, “Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer,” Clinical Infectious Diseases, vol. 41, no. 1, pp. 60–66, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Llata, D. B. Blossom, H. J. Khoury et al., “A cluster of mucormycosis infections in hematology patients: challenges in investigation and control of invasive mold infections in high-risk patient populations,” Diagnostic Microbiology and Infectious Disease, vol. 71, no. 1, pp. 72–80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Saegeman, J. Maertens, W. Meersseman, I. Spriet, E. Verbeken, and K. Lagrou, “Increasing incidence of Mucormycosis in university hospital, Belgium,” Emerging Infectious Diseases, vol. 16, no. 9, pp. 1456–1458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Bodro, N. Sabé, A. Gomila et al., “Risk factors, clinical characteristics, and outcomes of invasive fungal infections in solid organ transplant recipients,” Transplantation Proceedings, vol. 44, no. 9, pp. 2682–2685, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. N. G. Almyroudis, D. A. Sutton, P. Linden, M. G. Rinaldi, J. Fung, and S. Kusne, “Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature,” American Journal of Transplantation, vol. 6, no. 10, pp. 2365–2374, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. K. W. Seo, D. H. Kim, S. K. Sohn et al., “Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 36, no. 12, pp. 1089–1095, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. P.-Y. Bochud, J. W. Chien, K. A. Marr et al., “Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation,” The New England Journal of Medicine, vol. 359, no. 17, pp. 1766–1777, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Cunha, F. Aversa, J. F. Lacerda et al., “Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation,” The New England Journal of Medicine, vol. 370, no. 5, pp. 421–432, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. A. K. Zaas, G. Liao, J. W. Chien et al., “Plasminogen alleles influence susceptibility to invasive aspergillosis,” PLoS Genetics, vol. 4, no. 6, Article ID e1000101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Lambourne, D. Agranoff, R. Herbrecht et al., “Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients,” Clinical Infectious Diseases, vol. 49, no. 10, pp. 1486–1491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Singh, S. Husain, and the AST Infectious Diseases Community of Practice, “Invasive aspergillosis in solid organ transplant recipients,” The American Journal of Transplantation, vol. 9, pp. S180–S191, 2009. View at Publisher · View at Google Scholar
  51. N. Singh and H.-Y. Sun, “Iron overload and unique susceptibility of liver transplant recipients to disseminated disease due to opportunistic pathogens,” Liver Transplantation, vol. 14, no. 9, pp. 1249–1255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Rammaert, F. Lanternier, J.-R. Zahar et al., “Healthcare-associated mucormycosis,” Clinical Infectious Diseases, vol. 54, no. 1, pp. S44–S54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. B. D. Alexander, W. A. Schell, A. M. Siston et al., “Fatal apophysomyces elegans infection transmitted by deceased donor renal allografts,” American Journal of Transplantation, vol. 10, no. 9, pp. 2161–2167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Shoham, F. Hinestrosa, J. Moore Jr., S. O'Donnell, M. Ruiz, and J. Light, “Invasive filamentous fungal infections associated with renal transplant tourism,” Transplant Infectious Disease, vol. 12, no. 4, pp. 371–374, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. H. A. Carneiro, J. J. Coleman, A. Restrepo, and E. Mylonakis, “Fusarium infection in lung transplant patients: report of 6 cases and review of the literature,” Medicine, vol. 90, no. 1, pp. 69–80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Cooley, D. Spelman, K. Thursky, and M. Slavin, “Infection with Scedosporium apiospermum and S. prolificans, Australia,” Emerging Infectious Diseases, vol. 13, no. 8, pp. 1170–1177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Castiglioni, D. A. Sutton, M. G. Rinaldi, J. Fung, and S. Kusne, “Pseudallescheria boydii (Anamorph scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature,” Medicine, vol. 81, no. 5, pp. 333–348, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. C. T. Doligalski, K. Benedict, A. A. Cleveland et al., “Epidemiology of invasive mold infections in lung transplant recipients,” American Journal of Transplantation, vol. 14, no. 6, pp. 1328–1333, 2014. View at Publisher · View at Google Scholar
  59. N. Singh and S. Husain, “Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management,” Journal of Heart and Lung Transplantation, vol. 22, no. 3, pp. 258–266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. T. J. Walsh, E. J. Anaissie, D. W. Denning et al., “Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America,” Clinical Infectious Diseases, vol. 46, no. 3, pp. 327–360, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Irtan, M. Lamerain, F. Lesage et al., “Mucormycosis as a rare cause of severe gastrointestinal bleeding after multivisceral transplantation,” Transplant Infectious Disease, vol. 15, no. 6, pp. E235–E238, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Sampathkumar and C. V. Paya, “Fusarium infection after solid-organ transplantation,” Clinical Infectious Diseases, vol. 32, no. 8, pp. 1237–1240, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Y. Park, S. H. Kim, S. H. Choi et al., “Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients,” Transplant Infectious Disease, vol. 12, no. 4, pp. 309–315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Von Eiff, N. Roos, R. Schulten, M. Hesse, M. Zuhlsdorf, and J. Van de Loo, “Pulmonary aspergillosis: early diagnosis improves survival,” Respiration, vol. 62, no. 6, pp. 341–347, 1995. View at Publisher · View at Google Scholar · View at Scopus
  65. J. J. Tarrand, M. Lichterfeld, I. Warraich et al., “Diagnosis of invasive septate mold infections: a correlation of microbiological culture and histologic or cytologic examination,” American Journal of Clinical Pathology, vol. 119, no. 6, pp. 854–858, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Cuenca-Estrella, M. Bassetti, C. Lass-Flörl, Z. Ráčil, M. Richardson, and T. R. Rogers, “Detection and investigation of invasive mould disease,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 1, pp. i15–i24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. B. C. Cahill, J. R. Hibbs, K. Savik et al., “Aspergillus airway colonization and invasive disease after lung transplantation,” Chest, vol. 112, no. 5, pp. 1160–1164, 1997. View at Publisher · View at Google Scholar · View at Scopus
  68. D. P. Kontoyiannis, V. C. Wessel, G. P. Bodey, and K. V. I. Rolston, “Zygomycosis in the 1990s in a tertiary-care cancer center,” Clinical Infectious Diseases, vol. 30, no. 6, pp. 851–856, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Husain, D. L. Paterson, S. M. Studer et al., “Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients,” Transplantation, vol. 83, no. 10, pp. 1330–1336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Nucci, F. Carlesse, P. Cappellano et al., “Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing,” PLoS ONE, vol. 9, no. 1, Article ID e87784, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. D. P. Kontoyiannis and R. E. Lewis, “How I treat mucormycosis,” Blood, vol. 118, no. 5, pp. 1216–1224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. O. A. Cornely, S. Arikan-Akdagli, E. Dannaoui et al., “ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013,” Clinical Microbiology and Infection, vol. 20, no. 3, pp. 5–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. F. Lamoth, M. Cruciani, C. Mengoli et al., “β-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3),” Clinical Infectious Diseases, vol. 54, no. 5, pp. 633–643, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. E. de Carolis, B. Posteraro, C. Lass-Flörl et al., “Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry,” Clinical Microbiology and Infection, vol. 18, no. 5, pp. 475–484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. W. Schrödl, T. Heydel, V. U. Schwartze et al., “Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry,” Journal of Clinical Microbiology, vol. 50, no. 2, pp. 419–427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Sitterlé, S. Giraud, J. Leto et al., “Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and accurate identification of pseudallescheria/scedosporium species,” Clinical Microbiology and Infection, vol. 20, no. 9, pp. 929–935, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. S. A. Balajee, R. Kano, J. W. Baddley et al., “Molecular identification of Aspergillus species collected for the transplant-associated infection surveillance network,” Journal of Clinical Microbiology, vol. 47, no. 10, pp. 3138–3141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. M.-L. Luong, C. J. Clancy, A. Vadnerkar et al., “Comparison of an aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients,” Clinical Infectious Diseases, vol. 52, no. 10, pp. 1218–1226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Lass-Flörl, G. Resch, D. Nachbaur et al., “The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients,” Clinical Infectious Diseases, vol. 45, no. 7, pp. e101–e104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Garcia-Hermoso, E. Dannaoui, O. Lortholary, and F. Dromer, “Agents of systemic and subcutaneous mucormycosis and entomophthoromycosis,” in Manual of Clinical Microbiology, American Society for Microbiology, Ed., chapter 119, American Society for Microbiology, Washington, DC, USA, 10th edition, 2011. View at Google Scholar
  81. L. Potenza, D. Vallerini, P. Barozzi et al., “Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients,” Blood, vol. 118, no. 20, pp. 5416–5419, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Hot, C. Maunoury, S. Poiree et al., “Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections,” Clinical Microbiology and Infection, vol. 17, no. 3, pp. 409–417, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Herbrecht, D. W. Denning, T. F. Patterson et al., “Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis,” The New England Journal of Medicine, vol. 347, no. 6, pp. 408–415, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Nucci, E. J. Anaissie, F. Queiroz-Telles et al., “Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection,” Cancer, vol. 98, no. 2, pp. 315–319, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. A. S. Ibrahim, V. Avanessian, B. Spellberg, and J. E. Edwards Jr., “Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 10, pp. 3343–3344, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. A. H. Saad, D. D. DePestel, and P. L. Carver, “Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants,” Pharmacotherapy, vol. 26, no. 12 I, pp. 1730–1744, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Sansone-Parsons, G. Krishna, M. Martinho, B. Kantesaria, S. Gelone, and T. G. Mant, “Effect of oral posaconazole on the pharmacokinetics of cyclosporins and tacrolimus,” Pharmacotherapy, vol. 27, no. 6, pp. 825–834, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. J. A. Dowell, M. Stogniew, D. Krause, T. Henkel, and I. E. Weston, “Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine,” The Journal of Clinical Pharmacology, vol. 45, no. 2, pp. 227–233, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. R. A. Wermers, K. Cooper, R. R. Razonable et al., “Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy,” Clinical Infectious Diseases, vol. 52, no. 5, pp. 604–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. O. Epaulard, C. Villier, P. Ravaud et al., “A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study,” Clinical Infectious Diseases, vol. 57, no. 12, pp. e182–e188, 2013. View at Publisher · View at Google Scholar
  91. D. Lebeaux, F. Lanternier, C. Elie et al., “Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 12, pp. 5224–5229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. W. B. Park, N.-H. Kim, K.-H. Kim et al., “The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial,” Clinical Infectious Diseases, vol. 55, no. 8, pp. 1080–1087, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. M. J. Dolton, J. E. Ray, S. C.-A. Chen, K. Ng, L. Pont, and A. J. McLachlan, “Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 11, pp. 5503–5510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Wang, S. Chen, J. Sun et al., “Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections,” Journal of Antimicrobial Chemotherapy, vol. 69, no. 2, pp. 463–470, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. W. Kloezen, J. F. Meis, I. Curfs-Breuker, A. H. Fahal, and W. W. J. Van De Sande, “In vitro antifungal activity of isavuconazole against Madurella mycetomatis,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 11, pp. 6054–6056, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. ECCMID, “SECURE study,” in Proceedings of the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID '14), Barcelona, Spain, May 2014.
  97. J. Meletiadis, J. F. G. M. Meis, J. W. Mouton et al., “In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 1, pp. 62–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Schemuth, S. Dittmer, M. Lackner et al., “In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis,” Mycoses, vol. 56, no. 3, pp. 297–303, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Schwartz, A. Reisman, and P. F. Troke, “The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis,” Infection, vol. 39, no. 3, pp. 201–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. P. E. Verweij, N. J. M. Cox, and J. F. G. Meis, “Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 16, no. 1, pp. 26–28, 1997. View at Publisher · View at Google Scholar · View at Scopus
  101. M. O. Musa, A. Al Eisa, M. Halim et al., “The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years,” British Journal of Haematology, vol. 108, no. 3, pp. 544–548, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. I. I. Raad, R. Y. Hachem, R. Herbrecht et al., “Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions,” Clinical Infectious Diseases, vol. 42, no. 10, pp. 1398–1403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. G. Chamilos, R. E. Lewis, and D. P. Kontoyiannis, “Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis,” Clinical Infectious Diseases, vol. 47, no. 4, pp. 503–509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. R. E. Lewis, N. D. Albert, G. Liao, J. Hou, R. A. Prince, and D. P. Kontoyiannis, “Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 1298–1304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. H.-Y. Sun, J. M. Aguado, H. Bonatti et al., “Pulmonary zygomycosis in solid organ transplant recipients in the current era,” American Journal of Transplantation, vol. 9, no. 9, pp. 2166–2171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. F. Lanternier, S. Poiree, and C. Elie, “Pilot prospective study of high dose (10 mg/kg/day) liposomal amphotericin B for the initial treat- ment of mucormycosis: “AMBIZYGO” trial (M-1707),” in Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif, USA, 2012.
  107. C. Reed, R. Bryant, A. S. Ibrahim et al., “Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis,” Clinical Infectious Diseases, vol. 47, no. 3, pp. 364–371, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. A. S. Ibrahim, T. Gebremariam, J. A. Schwartz, J. E. Edwards Jr., and B. Spellberg, “Posaconazole mono- or combination therapy for treatment of murine zygomycosis,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 772–775, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. R. N. Greenberg, K. Mullane, J.-A. H. van Burik et al., “Posaconazole as salvage therapy for zygomycosis,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 1, pp. 126–133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. J.-A. H. van Burik, R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis, “Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases,” Clinical Infectious Diseases, vol. 42, no. 7, pp. e61–e65, 2006. View at Google Scholar
  111. M. E. Henry, N. R. Bolo, C. S. Zuo et al., “Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 11, pp. 5271–5276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. D. M. Li and G. S. de Hoog, “Cerebral phaeohyphomycosis—a cure at what lengths?” The Lancet Infectious Diseases, vol. 9, no. 6, pp. 376–383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. H.-Y. Sun, G. Forrest, K. L. Gupta et al., “Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients,” Transplantation, vol. 90, no. 1, pp. 85–92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Tedder, J. A. Spratt, M. P. Anstadt, S. S. Hegde, S. D. Tedder, and J. E. Lowe, “Pulmonary mucormycosis: results of medical and surgical therapy,” The Annals of Thoracic Surgery, vol. 57, no. 4, pp. 1044–1050, 1994. View at Publisher · View at Google Scholar · View at Scopus
  115. P. Vironneau, R. Kania, G. Morizot et al., “Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival,” Clinical Infectious Diseases, vol. 20, no. 5, pp. O336–O339, 2014. View at Publisher · View at Google Scholar
  116. F. M. Lupinetti, R. H. Giller, and M. E. Trigg, “Operative treatment of Fusarium fungal infection of the lung,” Annals of Thoracic Surgery, vol. 49, no. 6, pp. 991–992, 1990. View at Publisher · View at Google Scholar · View at Scopus
  117. S. G. Revankar, J. E. Patterson, D. A. Sutton, R. Pullen, and M. G. Rinaldi, “Disseminated phaeohyphomycosis: review of an emerging mycosis,” Clinical Infectious Diseases, vol. 34, no. 4, pp. 467–476, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. J. M. Rowe, J. W. Andersen, J. J. Mazza et al., “A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490),” Blood, vol. 86, no. 2, pp. 457–462, 1995. View at Google Scholar · View at Scopus
  119. A. S. Ibrahim, T. Gebermariam, Y. Fu et al., “The iron chelator deferasirox protects mice from mucormycosis through iron starvation,” The Journal of Clinical Investigation, vol. 117, no. 9, pp. 2649–2657, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. B. Spellberg, A. S. Ibrahim, P. V. Chin-Hong et al., “The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study: a randomized, double-blinded, placebo-controlled trial,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 3, Article ID dkr375, pp. 715–722, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. B. V. John, G. Chamilos, and D. P. Kontoyiannis, “Hyperbaric oxygen as an adjunctive treatment for zygomycosis,” Clinical Microbiology and Infection, vol. 11, no. 7, pp. 515–517, 2005. View at Publisher · View at Google Scholar · View at Scopus
  122. G. Lukács, T. Papp, I. Nyilasi, E. Nagy, and C. Vágvölgyi, “Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin,” Journal of Clinical Microbiology, vol. 42, no. 11, pp. 5400–5402, 2004. View at Publisher · View at Google Scholar · View at Scopus
  123. J. Gavaldà, Y. Meije, J. Fortún et al., “Invasive fungal infections in solid organ transplant recipients,” Clinical Microbiology and Infection, vol. 20, no. s7, pp. 27–48, 2014. View at Publisher · View at Google Scholar
  124. J. W. Baddley, D. R. Andes, K. A. Marr et al., “Factors associated with mortality in transplant patients with invasive aspergillosis,” Clinical Infectious Diseases, vol. 50, pp. 1559–1567, 2010. View at Publisher · View at Google Scholar
  125. M. Nucci and E. Anaissie, “Fusarium infections in immunocompromised patients,” Clinical Microbiology Reviews, vol. 20, no. 4, pp. 695–704, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. A. M. Tortorano, M. Richardson, E. Roilides et al., “ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others,” Clinical Microbiology and Infection, vol. 20, supplement 3, pp. 27–46, 2014. View at Publisher · View at Google Scholar
  127. E. M. Marom, A. M. Holmes, J. F. Bruzzi, M. T. Truong, P. J. O'Sullivan, and D. P. Kontoyiannis, “Imaging of pulmonary fusariosis in patients with hematologic malignancies,” American Journal of Roentgenology, vol. 190, no. 6, pp. 1605–1609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. S. P. Georgiadou, N. V. Sipsas, E. M. Marom, and D. P. Kontoyiannis, “The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts,” Clinical Infectious Diseases, vol. 52, no. 9, pp. 1144–1155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. E. Marchiori, G. Zanetti, D. L. Escuissato et al., “Reversed halo sign: high-resolution CT scan findings in 79 patients,” Chest, vol. 141, no. 5, pp. 1260–1266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. J. A. Ribes, C. L. Vanover-Sams, and D. J. Baker, “Zygomycetes in human disease,” Clinical Microbiology Reviews, vol. 13, no. 2, pp. 236–301, 2000. View at Publisher · View at Google Scholar · View at Scopus
  131. C. Mengoli, M. Cruciani, R. A. Barnes, J. Loeffler, and J. P. Donnelly, “Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 9, no. 2, pp. 89–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Chowdhary, J. F. Meis, J. Guarro et al., “ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi,” Clinical Microbiology and Infection, vol. 20, supplement 3, pp. 47–75, 2014. View at Publisher · View at Google Scholar
  133. D. E. Karageorgopoulos, E. K. Vouloumanou, F. Ntziora, A. Michalopoulos, P. I. Rafailidis, and M. E. Falagas, “β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis,” Clinical Infectious Diseases, vol. 52, no. 6, pp. 750–770, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. Y. Lu, Y.-Q. Chen, Y.-L. Guo, S.-M. Qin, C. Wu, and K. Wang, “Diagnosis of invasive fungal disease using serum (1→3)-β-D-glucan: a bivariate meta-analysis,” Internal Medicine, vol. 50, no. 22, pp. 2783–2791, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. C. D. Pfeiffer, J. P. Fine, and N. Safdar, “Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis,” Clinical Infectious Diseases, vol. 42, no. 10, pp. 1417–1427, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. S. Husain, C. J. Clancy, M. H. Nguyen et al., “Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid,” Clinical and Vaccine Immunology, vol. 15, no. 12, pp. 1760–1763, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. J. W. Baddley, K. A. Marr, D. R. Andes et al., “Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection surveillance network,” Journal of Clinical Microbiology, vol. 47, no. 10, pp. 3271–3275, 2009. View at Publisher · View at Google Scholar · View at Scopus